WAYMADE-MARAVIROC DIN 02561948
Health Canada record
| Active ingredient(s) | MARAVIROC 300 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AX09 MARAVIROC |
| Original market date | 11-May-2026 |
| Current status date | 11-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Waymade Canada Inc. — licence 3-002646, currently licensed, last inspection rating C (2026-02-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MARAVIROC
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02299844 | CELSENTRI | VIIV HEALTHCARE ULC | Tablet | MARAVIROC 150 MG | Marketed |
| 02299852 | CELSENTRI | VIIV HEALTHCARE ULC | Tablet | MARAVIROC 300 MG | Marketed |
| 02561921 | WAYMADE-MARAVIROC | WAYMADE CANADA INC. | Tablet | MARAVIROC 150 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36186 | 2025-10-16 | Abbreviated New Drug Submission (ANDS) |
International API supply for MARAVIROC
5 active FDA Drug Master Files.
Request a quote for WAYMADE-MARAVIROC